tiprankstipranks
Trending News
More News >
Ascendis Pharma (ASND)
NASDAQ:ASND
US Market

Ascendis Pharma (ASND) Stock Forecast & Price Target

Compare
585 Followers
See the Price Targets and Ratings of:

ASND Analyst Ratings

Strong Buy
13Ratings
Strong Buy
13 Buy
0 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Ascendis
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ASND Stock 12 Month Forecast

Average Price Target

$221.85
▲(27.21%Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Ascendis Pharma in the last 3 months. The average price target is $221.85 with a high forecast of $289.00 and a low forecast of $194.00. The average price target represents a 27.21% change from the last price of $174.40.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"124":"$124","207":"$207","290":"$290","165.5":"$165.5","248.5":"$248.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":289,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$289.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":221.85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$221.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":194,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$194.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[124,165.5,207,248.5,290],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,175.69,184.40615384615384,193.1223076923077,201.83846153846153,210.55461538461537,219.27076923076922,227.98692307692306,236.70307692307694,245.41923076923075,254.13538461538462,262.85153846153844,271.5676923076923,280.2838461538462,{"y":289,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,175.69,179.24076923076922,182.79153846153847,186.34230769230768,189.89307692307693,193.44384615384615,196.99461538461537,200.54538461538462,204.09615384615384,207.6469230769231,211.1976923076923,214.74846153846153,218.29923076923077,{"y":221.85,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,175.69,177.09846153846155,178.50692307692307,179.91538461538462,181.32384615384615,182.7323076923077,184.14076923076922,185.54923076923077,186.9576923076923,188.36615384615385,189.77461538461537,191.18307692307692,192.59153846153845,{"y":194,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":135.1,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.98,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":136.53,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":138.45,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":146.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.28,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.51,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.67,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.66,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.58,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$289.00Average Price Target$221.85Lowest Price Target$194.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on ASND
Tazeen AhmadBank of America Securities
Bank of America Securities
$196$201
Buy
15.25%
Upside
Reiterated
06/02/25
Bank of America Securities Remains a Buy on Ascendis Pharma (ASND)
Stifel Nicolaus Analyst forecast on ASND
Alex Thompson CFAStifel Nicolaus
Stifel Nicolaus
$212
Buy
21.56%
Upside
Reiterated
05/27/25
Ascendis Pharma (ASND) Gets a Buy from Stifel Nicolaus
Morgan Stanley Analyst forecast on ASND
Vikram PurohitMorgan Stanley
Morgan Stanley
$250
Buy
43.35%
Upside
Reiterated
05/27/25
Morgan Stanley Sticks to Its Buy Rating for Ascendis Pharma (ASND)
Wells Fargo Analyst forecast on ASND
Derek ArchilaWells Fargo
Wells Fargo
$289
Buy
65.71%
Upside
Reiterated
05/21/25
Optimistic Outlook for Ascendis Pharma: Buy Rating Driven by COACH Phase 2 Trial and Yorvipath Launch
Cantor Fitzgerald Analyst forecast on ASND
Li WatsekCantor Fitzgerald
Cantor Fitzgerald
$280$200
Buy
14.68%
Upside
Reiterated
05/12/25
Cantor Fitzgerald Remains a Buy on Ascendis Pharma (ASND)
TD Cowen Analyst forecast on ASND
Yaron WerberTD Cowen
TD Cowen
$162$194
Buy
11.24%
Upside
Reiterated
05/02/25
Promising Growth and Investment Potential for Ascendis Pharma Amid Strong Yorvipath Launch and Upcoming Catalysts
J.P. Morgan Analyst forecast on ASND
Jessica FyeJ.P. Morgan
J.P. Morgan
$200$245
Buy
40.48%
Upside
Reiterated
05/02/25
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), Madrigal Pharmaceuticals (NASDAQ: MDGL) and Alphatec Holdings (NASDAQ: ATEC)
Oppenheimer Analyst forecast on ASND
Leland GershellOppenheimer
Oppenheimer
$180$215
Buy
23.28%
Upside
Reiterated
05/02/25
Ascendis Pharma price target raised to $215 from $180 at OppenheimerAscendis Pharma price target raised to $215 from $180 at Oppenheimer
Leerink Partners Analyst forecast on ASND
Joseph SchwartzLeerink Partners
Leerink Partners
$190$200
Buy
14.68%
Upside
Reiterated
05/01/25
Ascendis Pharma's Strong Yorvipath Launch and Promising Pipeline Boost Buy Rating and Price Target
Wedbush Analyst forecast on ASND
Yun ZhongWedbush
Wedbush
$181$212
Buy
21.56%
Upside
Reiterated
05/01/25
Ascendis Pharma: Strong Market Position and Growth Potential Justify Buy Rating
RBC Capital Analyst forecast on ASND
Luca IssiRBC Capital
RBC Capital
$205$210
Buy
20.41%
Upside
Reiterated
05/01/25
RBC Capital Remains a Buy on Ascendis Pharma (ASND)
Evercore ISI
$260
Buy
49.08%
Upside
Reiterated
04/25/25
Ascendis Pharma (ASND) Gets a Buy from Evercore ISI
UBS
$196
Buy
12.39%
Upside
Reiterated
03/27/25
UBS reiterates Buy Rating on Ascendis Pharma (ASND)UBS analyst Eliana Merle reiterated a Buy rating and $196.00 price target on Ascendis Pharma (NASDAQ: ASND).
Goldman Sachs Analyst forecast on ASND
Paul ChoiGoldman Sachs
Goldman Sachs
$200$225
Buy
29.01%
Upside
Reiterated
02/13/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jefferies Analyst forecast on ASND
Kelly ShiJefferies
Jefferies
$194
Buy
11.24%
Upside
Assigned
12/17/24
Ascendis Pharma (ASND) PT Raised to $194 at JefferiesJefferies analyst Kelly Shi raised the price target on Ascendis Pharma (NASDAQ: ASND) to $194.00 (from $191.00) while maintaining a Buy rating.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on ASND
Tazeen AhmadBank of America Securities
Bank of America Securities
$196$201
Buy
15.25%
Upside
Reiterated
06/02/25
Bank of America Securities Remains a Buy on Ascendis Pharma (ASND)
Stifel Nicolaus Analyst forecast on ASND
Alex Thompson CFAStifel Nicolaus
Stifel Nicolaus
$212
Buy
21.56%
Upside
Reiterated
05/27/25
Ascendis Pharma (ASND) Gets a Buy from Stifel Nicolaus
Morgan Stanley Analyst forecast on ASND
Vikram PurohitMorgan Stanley
Morgan Stanley
$250
Buy
43.35%
Upside
Reiterated
05/27/25
Morgan Stanley Sticks to Its Buy Rating for Ascendis Pharma (ASND)
Wells Fargo Analyst forecast on ASND
Derek ArchilaWells Fargo
Wells Fargo
$289
Buy
65.71%
Upside
Reiterated
05/21/25
Optimistic Outlook for Ascendis Pharma: Buy Rating Driven by COACH Phase 2 Trial and Yorvipath Launch
Cantor Fitzgerald Analyst forecast on ASND
Li WatsekCantor Fitzgerald
Cantor Fitzgerald
$280$200
Buy
14.68%
Upside
Reiterated
05/12/25
Cantor Fitzgerald Remains a Buy on Ascendis Pharma (ASND)
TD Cowen Analyst forecast on ASND
Yaron WerberTD Cowen
TD Cowen
$162$194
Buy
11.24%
Upside
Reiterated
05/02/25
Promising Growth and Investment Potential for Ascendis Pharma Amid Strong Yorvipath Launch and Upcoming Catalysts
J.P. Morgan Analyst forecast on ASND
Jessica FyeJ.P. Morgan
J.P. Morgan
$200$245
Buy
40.48%
Upside
Reiterated
05/02/25
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), Madrigal Pharmaceuticals (NASDAQ: MDGL) and Alphatec Holdings (NASDAQ: ATEC)
Oppenheimer Analyst forecast on ASND
Leland GershellOppenheimer
Oppenheimer
$180$215
Buy
23.28%
Upside
Reiterated
05/02/25
Ascendis Pharma price target raised to $215 from $180 at OppenheimerAscendis Pharma price target raised to $215 from $180 at Oppenheimer
Leerink Partners Analyst forecast on ASND
Joseph SchwartzLeerink Partners
Leerink Partners
$190$200
Buy
14.68%
Upside
Reiterated
05/01/25
Ascendis Pharma's Strong Yorvipath Launch and Promising Pipeline Boost Buy Rating and Price Target
Wedbush Analyst forecast on ASND
Yun ZhongWedbush
Wedbush
$181$212
Buy
21.56%
Upside
Reiterated
05/01/25
Ascendis Pharma: Strong Market Position and Growth Potential Justify Buy Rating
RBC Capital Analyst forecast on ASND
Luca IssiRBC Capital
RBC Capital
$205$210
Buy
20.41%
Upside
Reiterated
05/01/25
RBC Capital Remains a Buy on Ascendis Pharma (ASND)
Evercore ISI
$260
Buy
49.08%
Upside
Reiterated
04/25/25
Ascendis Pharma (ASND) Gets a Buy from Evercore ISI
UBS
$196
Buy
12.39%
Upside
Reiterated
03/27/25
UBS reiterates Buy Rating on Ascendis Pharma (ASND)UBS analyst Eliana Merle reiterated a Buy rating and $196.00 price target on Ascendis Pharma (NASDAQ: ASND).
Goldman Sachs Analyst forecast on ASND
Paul ChoiGoldman Sachs
Goldman Sachs
$200$225
Buy
29.01%
Upside
Reiterated
02/13/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jefferies Analyst forecast on ASND
Kelly ShiJefferies
Jefferies
$194
Buy
11.24%
Upside
Assigned
12/17/24
Ascendis Pharma (ASND) PT Raised to $194 at JefferiesJefferies analyst Kelly Shi raised the price target on Ascendis Pharma (NASDAQ: ASND) to $194.00 (from $191.00) while maintaining a Buy rating.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ascendis Pharma

1 Month
xxx
Success Rate
11/15 ratings generated profit
73%
Average Return
+6.66%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 73.33% of your transactions generating a profit, with an average return of +6.66% per trade.
3 Months
xxx
Success Rate
19/25 ratings generated profit
76%
Average Return
+11.94%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 76.00% of your transactions generating a profit, with an average return of +11.94% per trade.
1 Year
Tazeen AhmadBank of America Securities
Success Rate
24/29 ratings generated profit
83%
Average Return
+23.02%
reiterated a buy rating 3 days ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 82.76% of your transactions generating a profit, with an average return of +23.02% per trade.
2 Years
xxx
Success Rate
15/15 ratings generated profit
100%
Average Return
+50.46%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +50.46% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ASND Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
11
10
9
7
6
Buy
23
25
22
23
16
Hold
15
14
11
7
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
49
49
42
37
25
In the current month, ASND has received 22 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. ASND average Analyst price target in the past 3 months is 221.85.
Each month's total comprises the sum of three months' worth of ratings.

ASND Financial Forecast

ASND Earnings Forecast

Next quarter’s earnings estimate for ASND is -$1.55 with a range of -$2.48 to -$0.94. The previous quarter’s EPS was -$1.79. ASND beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year ASND has Outperformed its overall industry.
Next quarter’s earnings estimate for ASND is -$1.55 with a range of -$2.48 to -$0.94. The previous quarter’s EPS was -$1.79. ASND beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year ASND has Outperformed its overall industry.

ASND Sales Forecast

Next quarter’s sales forecast for ASND is $152.29M with a range of $123.69M to $177.16M. The previous quarter’s sales results were $106.25M. ASND beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year ASND has Outperformed its overall industry.
Next quarter’s sales forecast for ASND is $152.29M with a range of $123.69M to $177.16M. The previous quarter’s sales results were $106.25M. ASND beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year ASND has Outperformed its overall industry.

ASND Stock Forecast FAQ

What is ASND’s average 12-month price target, according to analysts?
Based on analyst ratings, Ascendis Pharma’s 12-month average price target is 221.85.
    What is ASND’s upside potential, based on the analysts’ average price target?
    Ascendis Pharma has 27.21% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ASND a Buy, Sell or Hold?
          Ascendis Pharma has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Ascendis Pharma’s price target?
            The average price target for Ascendis Pharma is 221.85. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $289.00 ,the lowest forecast is $194.00. The average price target represents 27.21% Increase from the current price of $174.4.
              What do analysts say about Ascendis Pharma?
              Ascendis Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of ASND?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis